Ardena Pamplona
Ardena Pamplona is recorded as a service provider in 6 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 6 of 6 trials · Latest update first
A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-Finding Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics of iN1011-N17-02 in Patients with Post herpetic Neuralgia (PHN)
Sponsor iN Therapeutics Co. Ltd.
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Phase 2 Study to Evaluate Efficacy, Safety, and Pharmacokinetics of PBF-999 in the Treatment of Patients with Prader-Willi Syndrome.
Sponsor Palo Biofarma S.L.
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Multicenter, Two-arm, Double-blind, Double dummy, Parallel-group Study for efficacy and safety evaluation of prolonged release formulation of Betahistine PR 48 mg once daily in comparison with conventional release formulation of Betahistine IR 24 mg, twice daily in treatment of adult patients with Menière's disease
Sponsor Intas Pharmaceuticals Limited
- Start (EU)
- Latest update
- Estimated end
- Not reported
A phase IIa, open label, single centre study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of orally dosed MBF-015 in Huntington's disease patients
Sponsor Medibiofarma S.L.
- Start (EU)
- Latest update
- Estimated end
- Not reported
KANDOVA - A two-part Phase Ib/IIa study to evaluate the safety and tolerability of KAND567, in combination with carboplatin therapy, and to determine the Recommended Phase II Dose (RPIID) of KAND567. An open-label, multicenter dose escalation study with an expansion cohort in women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Sponsor Kancera AB
- Start (EU)
- Latest update
- Estimated end
- Not reported
A phase IIa, open label, Single-centre study to assess the initial antifibrotic efficacy, safety, tolerability, pharmacokinetic and pharmacodynamic profile of MBF-118 in Crohn’s disease patients with stenosis.
Sponsor Medibiofarma S.L.
- Start (EU)
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Ardena Pamplona?
The 2026-10-09 snapshot links Ardena Pamplona to 6 distinct CTIS trials. Recorded services include Medicinal product management, EU packaging, test and release of the medication, IMP manufacturing, packaging, labeling, release and supply management. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Ardena Pamplona?
The most frequently recorded therapeutic areas are Neurology, Pain Medicine. Recorded phases include Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Ardena Pamplona conducted?
The linked trials record locations in 6 countries, including Spain, Bulgaria, Denmark, Norway, Poland. These are trial locations, not confirmed office locations or countries where Ardena Pamplona delivered services.
What can this page tell me about Ardena Pamplona's trial experience?
Browse 6 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Ardena Pamplona. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Ardena Pamplona S.L.